A clinically guided HRT offering featuring estradiol cream, patches, and compounded progesterone is now available via Eden’s platform in most U.S. states.
Eden, the leading health platform connecting individuals with independent licensed providers and pharmacies focused on metabolic health, announced expanded access to female hormone therapy through its nationwide network. This new offering allows eligible individuals to consult with licensed healthcare professionals about treatment options related to hormonal changes during perimenopause and menopause. Services are available in all U.S. states except Arkansas and South Carolina.
Health Technology Insights: Sarepta Updates UK Dosing in ENVISION Study of ELEVIDYS
Eden connects members with independent licensed providers who, following a telehealth consultation, may prescribe a variety of therapies based on clinical judgment. These include FDA-approved estradiol 0.01% vaginal cream, a selection of transdermal estradiol patches (0.025–0.075 mg), and compounded sustained-release progesterone capsules (100–200 mg). Prescriptions are filled and shipped directly by licensed pharmacies when clinically appropriate.
“Our goal at Eden is to improve access to expert-guided care through a platform designed for safety, convenience, and personalization,” said Dr. Rebecca Emch, PharmD, VP of Pharmacy and Medical Operations at Eden. “We help members connect with providers who take the time to assess their needs and discuss appropriate treatment options.”
Eden’s telehealth process includes a secure medical intake, optional lab integration, and ongoing support for members who qualify. Treatments are only prescribed following clinical evaluation and are subject to provider discretion.
Health Technology Insights: Survey: Two-Thirds of U.S. Healthcare Workers Unsure on Nicotine’s Cancer Risk
Unlike quick-prescription platforms, Eden facilitates a process that prioritizes medical oversight, patient education, and personalized care. Providers may discuss hormone therapy options in the context of symptoms associated with perimenopause, menopause, and other related clinical considerations.
“At Eden, we believe midlife care should be accessible, informed, and centered on our member’s choice,” said Josh Khan, Eden Co-Founder and President. “For me, this mission is personal. I watched my own mom suffer through menopause without the support she deserved—and I had a front-row seat to how isolating that experience can be. The truth is, 100% of women go through menopause, but only about 5% seek treatment. That’s not because they don’t want help—it’s because help hasn’t been easy to find. At Eden, we’re working to change that by making it easier to connect with experienced network providers and trusted pharmacies. Our goal is to support a better path forward—one that gives women the opportunity to explore their options with confidence and compassion.”
Health Technology Insights: CEL-SCI’s Multikine Cancer Drug May Launch in Saudi Arabia by 2025
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
